Tranexamic Acid in Patients Undergoing Noncardiac Surgery.
Philip J DevereauxMaura MarcucciThomas W PainterDavid ConenVladimir LomivorotovDaniel I SesslerMatthew T V ChanFlavia K BorgesMaría J Martínez-ZapataChew Yin WangDenis XavierSandra N OforiMichael K WangSergey EfremovGiovanni LandoniYdo V KleinlugtenbeltWojciech SzczeklikDenis SchmartzAmit X GargTimothy G ShortMaria WittmannChristian S MeyhoffMohammed AmirDavid TorresAmeen PatelEmmanuelle DuceppeKurt RuetzlerJoel L ParlowVikas TandonEdith FleischmannCarisi A PolanczykAndre LamySergey V AstrakovMangala RaoWilliam Ka Kei WuKeyur BhattMiriam de NadalValery V LikhvantsevPilar PaniaguaHector J AguadoRichard P WhitlockMichael H McGillionMichael PrystajeckyJessica VincentJohn EikelboomIngrid CoplandKumar BalasubramanianAlparslan TuranShrikant I BangdiwalaDavid StilloPeter L GrossTeresa CafaroPascal AlfonsiPavel S RoshanovEmilie P Belley-CôtéJessica SpenceToby RichardsTomas VanHelderWilliam McIntyreGordon GuyattSalim YusufKate Leslienull nullPublished in: The New England journal of medicine (2022)
Among patients undergoing noncardiac surgery, the incidence of the composite bleeding outcome was significantly lower with tranexamic acid than with placebo. Although the between-group difference in the composite cardiovascular outcome was small, the noninferiority of tranexamic acid was not established. (Funded by the Canadian Institutes of Health Research and others; POISE-3 ClinicalTrials.gov number, NCT03505723.).